Denosumab for Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors: Incremental Benefit, Debatable Value The original article 2 presented two estimates for the ...
Safety of darolutamide (DARO) for nonmetastatic castration-resistant prostate cancer (nmCRPC) from extended follow-up in the phase III ARAMIS trial. This is an ASCO Meeting Abstract from the 2021 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results